首页> 外文期刊>Gastroenterology >Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation
【24h】

Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation

机译:检测肝脏移植后患者持续发生抗病毒剂的持续病毒性反应的患者患者患者

获取原文
获取原文并翻译 | 示例
           

摘要

Occult infection with hepatitis C virus (HCV) is defined as the presence of the HCV genome in either liver tissue or peripheral blood monocytes, despite constant negative results from tests for HCV RNA in serum. We investigated whether patients who maintained a sustained virologic response 12 weeks after therapy (SVR12) with direct-acting antiviral (DAA) agents for recurrent HCV infection after liver transplantation had occult HCV infections. We performed a prospective study of 134 patients with recurrent HCV infection after liver transplantation who were treated with DAAs, with or without ribavirin, from 2014 through 2016 (129 patients achieved an SVR12). In >10% of the patients who achieved SVR12 (n = 14), serum levels of aminotransferases did not normalize during or after DAA therapy, or they normalized transiently but then increased sharply after DAA therapy. Of these 14 patients, 9 were assessed for occult HCV infection by reverse transcription quantitative polymerase chain reaction. This analysis revealed that 55% of these patients (n = 5) had an occult infection, with the detection of negative strand viral genome, indicating viral replication. These findings indicate the presence of occult HCV infection in some patients with abnormal levels of serum aminotransferases, despite SVR12 to DAAs for HCV infection after liver transplantation.
机译:尽管血清中HCV RNA的试验恒定的结果,但具有丙型肝炎病毒(HCV)的神秘感染(HCV)被定义为肝组织或外周血单核细胞中的HCV基因组。我们研究了治疗后12周(SVR12)在治疗后12周(SVR12)保持持续的病毒学反应的患者是否具有用于复发性HCV感染后的直接作用抗病毒(DAA)患者进行了肝脏移植治疗神秘的HCV感染。我们对肝脏移植治疗的肝脏移植治疗的肝脏移植患者进行了对134例患者的前瞻性研究,从2014年至2016年从2016年到2016年(129名患者达到了SVR12)。在> 10%的患者中获得SVR12(n = 14),血清氨基转移酶的血清水平在DAA治疗期间或之后没有正常化,或者它们在DAA治疗后瞬时归一化,但随后急剧增加。在这14名患者中,通过逆转录定量聚合酶链式反应评估9例潜水HCV感染。该分析显示,55%的这些患者(n = 5)具有神秘的感染,检测阴茎病毒基因组,表明病毒复制。这些发现表明,尽管肝移植后,在一些患有异常水平的血清氨基转移酶水平的患者中存在神经HCV感染。

著录项

  • 来源
    《Gastroenterology》 |2017年第3期|共12页
  • 作者单位

    Univ Southern Calif Keck Sch Med Div Gastrointestinal &

    Liver Dis Dept Med 1510 San Pablo St;

    Univ Southern Calif Keck Sch Med Div Gastrointestinal &

    Liver Dis Dept Med 1510 San Pablo St;

    Univ Southern Calif Keck Sch Med Div Gastrointestinal &

    Liver Dis Dept Med 1510 San Pablo St;

    Univ Washington Sch Med Dept Lab Med Seattle WA 98195 USA;

    Univ Southern Calif Keck Sch Med Dept Pathol Los Angeles CA USA;

    Univ Southern Calif Keck Sch Med Dept Pathol Los Angeles CA USA;

    Univ Southern Calif Keck Sch Med Div Gastrointestinal &

    Liver Dis Dept Med 1510 San Pablo St;

    Univ Southern Calif Keck Sch Med Div Gastrointestinal &

    Liver Dis Dept Med 1510 San Pablo St;

    Nationwide Childrens Hosp Res Inst Ctr Vaccines &

    Immun Columbus OH USA;

    Univ Washington Sch Med Dept Lab Med Seattle WA 98195 USA;

    Univ Southern Calif Keck Sch Med Div Gastrointestinal &

    Liver Dis Dept Med 1510 San Pablo St;

    Univ Southern Calif Keck Sch Med Div Gastrointestinal &

    Liver Dis Dept Med 1510 San Pablo St;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 消化系及腹部疾病;
  • 关键词

    Viral Hibernation; Treatment Outcome; Persistence; Limit of Detection;

    机译:病毒冬眠;治疗结果;持久性;检测限;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号